Oncostellae — Series A (estimated) · €500K partial: only one investor's ticket was disclosed

CDTI Innovación, through its Innvierte programme, agreed to enter the capital of Galician biopharma Oncostellae alongside the venture fund Bio & Tech Smart Capital FCRE (managed by Noso Capital). CDTI committed €500K; the total round size and Bio & Tech's ticket were not disclosed, and no venture stage was named. Oncostellae is developing OST-122 (JAK inhibitor for inflammatory bowel disease), OST-499 and OST-664.